Tempus AI, Inc.has announced a groundbreaking collaboration with biotechnology giant United Therapeutics (UT) to develop AI-powered medical software for early detection of pulmonary hypertension (PH).
The partnership aims to address the critical issue of delayed diagnosis in PH, a fatal and progressive heart and lung disease affecting approximately 1% of the population. Despite available treatments, PH diagnosis is often delayed by two or more years.
Tempus has developed an algorithm that analyzes 12-lead electrocardiogram (ECG) results to identify patients at risk of undiagnosed PH. The company recently presented initial findings at the American Thoracic Society International Conference in San Diego on May 22, 2024.
The research program will utilize Tempus Next, the company’s AI-enabled care pathway intelligence solution, to deploy the algorithm at participating centers. Up to 60 centers will be involved in a prospective clinical study to evaluate the algorithm’s effectiveness in detecting at-risk patients and tracking clinical outcomes.
Tempus plans to engage with the Food and Drug Administration (FDA) to align on regulatory requirements and validation expectations for this innovative AI-based algorithm.
“We aim to set a new standard for identifying patients with pulmonary hypertension by getting novel technology into the hands of clinicians to enable earlier diagnosis and more effective disease management,” said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. “Exploring this in a prospective multicenter study brings us one step closer to realizing the dream of data-driven precision medicine.”
This collaboration between Tempus AI and United Therapeutics represents a significant step forward in leveraging artificial intelligence for early disease detection and improved patient outcomes in the field of pulmonary hypertension.
